25 XP   0   0   10

Cue Biopharma
Buy, Hold or Sell?

Let's analyse Cue Biopharma together

PenkeI guess you are interested in Cue Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cue Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cue Biopharma

I send you an email if I find something interesting about Cue Biopharma.

Quick analysis of Cue Biopharma (30 sec.)










What can you expect buying and holding a share of Cue Biopharma? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.2%

What is your share worth?

Current worth
$0.79
Expected worth in 1 year
$0.12
How sure are you?
32.3%

+ What do you gain per year?

Total Gains per Share
$-0.67
Return On Investment
-41.0%

For what price can you sell your share?

Current Price per Share
$1.63
Expected price per share
$0 - $2.08
How sure are you?
50%

1. Valuation of Cue Biopharma (5 min.)




Live pricePrice per Share (EOD)

$1.63

Intrinsic Value Per Share

$-10.22 - $-11.92

Total Value Per Share

$-9.43 - $-11.13

2. Growth of Cue Biopharma (5 min.)




Is Cue Biopharma growing?

Current yearPrevious yearGrowGrow %
How rich?$37m$60.2m-$15m-33.2%

How much money is Cue Biopharma making?

Current yearPrevious yearGrowGrow %
Making money-$12.7m-$13.2m$524.7k4.1%
Net Profit Margin-2,319.7%-19,559.3%--

How much money comes from the company's main activities?

3. Financial Health of Cue Biopharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#518 / 1019

Most Revenue
#479 / 1019

Most Profit
#596 / 1019

Most Efficient
#867 / 1019

What can you expect buying and holding a share of Cue Biopharma? (5 min.)

Welcome investor! Cue Biopharma's management wants to use your money to grow the business. In return you get a share of Cue Biopharma.

What can you expect buying and holding a share of Cue Biopharma?

First you should know what it really means to hold a share of Cue Biopharma. And how you can make/lose money.

Speculation

The Price per Share of Cue Biopharma is $1.63. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cue Biopharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cue Biopharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.79. Based on the TTM, the Book Value Change Per Share is $-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cue Biopharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-17.5%-0.28-16.9%-0.29-18.0%-0.25-15.5%-0.22-13.3%
Usd Book Value Change Per Share-0.13-8.2%-0.17-10.3%0.000.1%0.000.1%0.031.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.13-8.2%-0.17-10.3%0.000.1%0.000.1%0.031.6%
Usd Price Per Share2.64-3.04-3.11-9.08-7.14-
Price to Earnings Ratio-2.32--2.73--2.62--9.64--7.90-
Price-to-Total Gains Ratio-19.74--19.08--73.57--6.80--16.88-
Price to Book Ratio3.36-3.09-2.31-7.95-6.39-
Price-to-Total Gains Ratio-19.74--19.08--73.57--6.80--16.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.63
Number of shares613
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.170.00
Usd Total Gains Per Share-0.170.00
Gains per Quarter (613 shares)-102.521.04
Gains per Year (613 shares)-410.104.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-410-42004-6
20-820-83008-2
30-1230-12400122
40-1640-16500176
50-2050-206002110
60-2461-247002514
70-2871-288002918
80-3281-329003322
90-3691-370003726
100-4101-411004130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.030.00.03.2%1.030.00.03.2%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%7.013.00.035.0%10.019.02.032.3%10.019.02.032.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.030.03.2%1.00.030.03.2%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%7.013.00.035.0%10.019.02.032.3%10.019.02.032.3%

Fundamentals of Cue Biopharma

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 05:27:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cue Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cue Biopharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • A Net Profit Margin of -737.7% means that $-7.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cue Biopharma:

  • The MRQ is -737.7%. The company is making a huge loss. -2
  • The TTM is -2,319.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-737.7%TTM-2,319.7%+1,582.0%
TTM-2,319.7%YOY-19,559.3%+17,239.6%
TTM-2,319.7%5Y-5,052.1%+2,732.4%
5Y-5,052.1%10Y-3,727.0%-1,325.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-737.7%-197.2%-540.5%
TTM-2,319.7%-210.4%-2,109.3%
YOY-19,559.3%-279.3%-19,280.0%
5Y-5,052.1%-436.8%-4,615.3%
10Y-3,727.0%-599.3%-3,127.7%
1.1.2. Return on Assets

Shows how efficient Cue Biopharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • -21.8% Return on Assets means that Cue Biopharma generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cue Biopharma:

  • The MRQ is -21.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -18.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.8%TTM-18.0%-3.8%
TTM-18.0%YOY-15.4%-2.6%
TTM-18.0%5Y-15.7%-2.3%
5Y-15.7%10Y-20.5%+4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.8%-13.6%-8.2%
TTM-18.0%-12.9%-5.1%
YOY-15.4%-11.9%-3.5%
5Y-15.7%-14.2%-1.5%
10Y-20.5%-16.2%-4.3%
1.1.3. Return on Equity

Shows how efficient Cue Biopharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • -36.2% Return on Equity means Cue Biopharma generated $-0.36 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cue Biopharma:

  • The MRQ is -36.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.2%TTM-28.7%-7.6%
TTM-28.7%YOY-22.0%-6.7%
TTM-28.7%5Y-23.5%-5.2%
5Y-23.5%10Y-27.3%+3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.2%-17.0%-19.2%
TTM-28.7%-16.1%-12.6%
YOY-22.0%-15.4%-6.6%
5Y-23.5%-20.0%-3.5%
10Y-27.3%-21.1%-6.2%

1.2. Operating Efficiency of Cue Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cue Biopharma is operating .

  • Measures how much profit Cue Biopharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • An Operating Margin of -751.0% means the company generated $-7.51  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cue Biopharma:

  • The MRQ is -751.0%. The company is operating very inefficient. -2
  • The TTM is -2,338.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-751.0%TTM-2,338.4%+1,587.5%
TTM-2,338.4%YOY-19,455.5%+17,117.1%
TTM-2,338.4%5Y-5,039.7%+2,701.2%
5Y-5,039.7%10Y-3,717.2%-1,322.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-751.0%-286.1%-464.9%
TTM-2,338.4%-224.4%-2,114.0%
YOY-19,455.5%-288.4%-19,167.1%
5Y-5,039.7%-475.2%-4,564.5%
10Y-3,717.2%-624.7%-3,092.5%
1.2.2. Operating Ratio

Measures how efficient Cue Biopharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.51 means that the operating costs are $8.51 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cue Biopharma:

  • The MRQ is 8.510. The company is inefficient in keeping operating costs low. -1
  • The TTM is 26.002. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.510TTM26.002-17.492
TTM26.002YOY205.411-179.410
TTM26.0025Y55.766-29.764
5Y55.76610Y42.878+12.888
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5102.997+5.513
TTM26.0023.247+22.755
YOY205.4113.766+201.645
5Y55.7665.675+50.091
10Y42.8787.857+35.021

1.3. Liquidity of Cue Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cue Biopharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.01 means the company has $3.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cue Biopharma:

  • The MRQ is 3.012. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.768. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.012TTM3.768-0.755
TTM3.768YOY6.917-3.149
TTM3.7685Y4.915-1.148
5Y4.91510Y6.512-1.597
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0123.930-0.918
TTM3.7684.251-0.483
YOY6.9175.436+1.481
5Y4.9156.045-1.130
10Y6.5126.363+0.149
1.3.2. Quick Ratio

Measures if Cue Biopharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • A Quick Ratio of 2.94 means the company can pay off $2.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cue Biopharma:

  • The MRQ is 2.940. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.916. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.940TTM3.916-0.976
TTM3.916YOY8.003-4.088
TTM3.9165Y5.471-1.556
5Y5.47110Y6.272-0.801
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9403.629-0.689
TTM3.9164.065-0.149
YOY8.0035.397+2.606
5Y5.4715.993-0.522
10Y6.2726.277-0.005

1.4. Solvency of Cue Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cue Biopharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cue Biopharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.40 means that Cue Biopharma assets are financed with 39.7% credit (debt) and the remaining percentage (100% - 39.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cue Biopharma:

  • The MRQ is 0.397. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.369. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.397TTM0.369+0.028
TTM0.369YOY0.299+0.070
TTM0.3695Y0.297+0.072
5Y0.29710Y0.236+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3970.332+0.065
TTM0.3690.334+0.035
YOY0.2990.268+0.031
5Y0.2970.366-0.069
10Y0.2360.390-0.154
1.4.2. Debt to Equity Ratio

Measures if Cue Biopharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cue Biopharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 65.9% means that company has $0.66 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cue Biopharma:

  • The MRQ is 0.659. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.587. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.659TTM0.587+0.072
TTM0.587YOY0.428+0.159
TTM0.5875Y0.452+0.135
5Y0.45210Y0.343+0.108
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6590.381+0.278
TTM0.5870.390+0.197
YOY0.4280.334+0.094
5Y0.4520.434+0.018
10Y0.3430.466-0.123

2. Market Valuation of Cue Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cue Biopharma generates.

  • Above 15 is considered overpriced but always compare Cue Biopharma to the Biotechnology industry mean.
  • A PE ratio of -2.32 means the investor is paying $-2.32 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cue Biopharma:

  • The EOD is -1.430. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.316. Based on the earnings, the company is expensive. -2
  • The TTM is -2.733. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.430MRQ-2.316+0.886
MRQ-2.316TTM-2.733+0.417
TTM-2.733YOY-2.622-0.111
TTM-2.7335Y-9.640+6.907
5Y-9.64010Y-7.900-1.741
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.430-2.315+0.885
MRQ-2.316-2.560+0.244
TTM-2.733-2.664-0.069
YOY-2.622-4.122+1.500
5Y-9.640-6.258-3.382
10Y-7.900-6.108-1.792
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cue Biopharma:

  • The EOD is -1.753. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.840. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.486. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.753MRQ-2.840+1.086
MRQ-2.840TTM-3.486+0.647
TTM-3.486YOY-3.400-0.086
TTM-3.4865Y-11.561+8.075
5Y-11.56110Y-9.472-2.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.753-3.067+1.314
MRQ-2.840-3.251+0.411
TTM-3.486-3.545+0.059
YOY-3.400-5.595+2.195
5Y-11.561-8.315-3.246
10Y-9.472-8.708-0.764
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cue Biopharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.36 means the investor is paying $3.36 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cue Biopharma:

  • The EOD is 2.072. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.356. Based on the equity, the company is fair priced.
  • The TTM is 3.091. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.072MRQ3.356-1.284
MRQ3.356TTM3.091+0.265
TTM3.091YOY2.306+0.785
TTM3.0915Y7.950-4.860
5Y7.95010Y6.386+1.565
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0721.905+0.167
MRQ3.3562.111+1.245
TTM3.0912.095+0.996
YOY2.3062.836-0.530
5Y7.9503.443+4.507
10Y6.3863.794+2.592
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cue Biopharma.

3.1. Institutions holding Cue Biopharma

Institutions are holding 35.472% of the shares of Cue Biopharma.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Slate Path Capital LP4.93890.1408240245500
2023-12-31BlackRock Inc4.8080.000223387652098159.8553
2023-12-31Vanguard Group Inc4.38480.0001213290579990.3764
2023-12-31Bleichroeder LP3.6081.029717550281000000132.4454
2023-12-31Geode Capital Management, LLC1.67190.0002813285508646.6714
2023-12-31State Street Corporation1.40550.0001683695-14500-2.0768
2023-12-31Robertson Stephens Wealth Management, LLC0.98370.076847850000
2023-12-31Dimensional Fund Advisors, Inc.0.94150.0004457985-108628-19.1715
2023-12-31Northern Trust Corp0.7840.00023813675268216.0281
2023-12-31Monaco Asset Management0.70360.2659342242-17497-4.8638
2023-12-31Millennium Management LLC0.56670.0003275645-38342-12.2113
2023-12-31Bank of America Corp0.54730.00012662277755541.1057
2023-12-31Advisory Research Inc0.52880.104725722500
2023-12-31Stifel Financial Corp0.39880.00061939754676331.7658
2023-12-31Nuveen Asset Management, LLC0.39380.000219153600
2023-12-31Morgan Stanley - Brokerage Accounts0.338601647064016832.2536
2023-12-31Carlson Capital LP0.24670.0253120000-15000-11.1111
2023-12-31Goldman Sachs Group Inc0.2398011664897535510.3071
2023-12-31Bank of New York Mellon Corp0.22480.000110935363416.1556
2023-12-31Sigma Planning Corp0.22380.0225108875-135830-55.5077
Total 27.9391.668213590417+1259925+9.3%

3.2. Funds holding Cue Biopharma

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.76930.0002134707800
2024-03-28iShares Russell 2000 ETF1.75650.00258544434110.0481
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.22850.001259756900
2024-01-31Fidelity Small Cap Index0.75120.003936538989832.5204
2024-03-28iShares Russell 2000 Growth ETF0.65310.0052317692-369-0.116
2024-02-29Fidelity Extended Market Index0.51590.0014250972-1216-0.4822
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.43910.001121360000
2024-02-29DFA US Small Cap I0.30890.0021502384659244.953
2024-02-29Vanguard Russell 2000 ETF0.27010.0029131387103248.5278
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.25920.002412610000
2023-09-30BlackRock Extended Mkt Composite0.24560.0021194676050.509
2023-12-31NT R2000 Growth Index Fund - NL0.21330.007410375800
2024-03-31BlackRock Extended Equity Market K0.21250.0013103371370.0358
2023-12-31NT R2000 Index Fund - NL0.20460.0036995151710.1721
2024-01-31TIAA-CREF Equity Index Instl0.20350.00069901000
2024-02-29Schwab Small Cap Index0.18220.00318861900
2023-12-31Northern Trust Russell 2000 Growth Index0.16730.00788136068419.1802
2023-12-31NT R2000 Growth Index Fund - L0.16730.00778136068419.1802
2023-12-31NT R2000 Index Fund - DC - NL - 20.16110.003678369-168-0.2139
2024-03-28iShares Micro-Cap ETF0.15830.01587698300
Total 10.86750.07575286280+79052+1.5%

3.3. Insider Transactions

Insiders are holding 4.726% of the shares of Cue Biopharma.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-25Anish SuriBUY40002.76
2023-08-14Daniel R PasseriBUY30002.86

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cue Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.134-0.167+25%0.001-12770%0.002-8021%0.025-627%
Book Value Per Share--0.7870.986-20%1.335-41%1.229-36%1.000-21%
Current Ratio--3.0123.768-20%6.917-56%4.915-39%6.512-54%
Debt To Asset Ratio--0.3970.369+8%0.299+33%0.297+34%0.236+68%
Debt To Equity Ratio--0.6590.587+12%0.428+54%0.452+46%0.343+92%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.285-0.276-3%-0.294+3%-0.253-11%-0.216-24%
Free Cash Flow Per Share---0.232-0.218-6%-0.233+0%-0.049-79%-0.066-72%
Free Cash Flow To Equity Per Share---0.131-0.154+17%0.065-302%0.166-179%0.181-172%
Gross Profit Margin--1.0561.014+4%1.000+6%1.003+5%1.002+5%
Intrinsic Value_10Y_max---11.915--------
Intrinsic Value_10Y_min---10.215--------
Intrinsic Value_1Y_max---0.939--------
Intrinsic Value_1Y_min---0.922--------
Intrinsic Value_3Y_max---3.015--------
Intrinsic Value_3Y_min---2.874--------
Intrinsic Value_5Y_max---5.326--------
Intrinsic Value_5Y_min---4.926--------
Market Cap73550979.000-69%124461450.960139219088.365-11%140446271.250-11%410184819.398-70%322364079.547-61%
Net Profit Margin---7.377-23.197+214%-195.593+2551%-50.521+585%-37.270+405%
Operating Margin---7.510-23.384+211%-194.555+2491%-50.397+571%-37.172+395%
Operating Ratio--8.51026.002-67%205.411-96%55.766-85%42.878-80%
Pb Ratio2.072-62%3.3563.091+9%2.306+46%7.950-58%6.386-47%
Pe Ratio-1.430+38%-2.316-2.733+18%-2.622+13%-9.640+316%-7.900+241%
Price Per Share1.630-62%2.6403.040-13%3.113-15%9.081-71%7.138-63%
Price To Free Cash Flow Ratio-1.753+38%-2.840-3.486+23%-3.400+20%-11.561+307%-9.472+234%
Price To Total Gains Ratio-12.189+38%-19.742-19.078-3%-73.566+273%-6.795-66%-16.881-14%
Quick Ratio--2.9403.916-25%8.003-63%5.471-46%6.272-53%
Return On Assets---0.218-0.180-18%-0.154-30%-0.157-28%-0.205-6%
Return On Equity---0.362-0.287-21%-0.220-39%-0.235-35%-0.273-25%
Total Gains Per Share---0.134-0.167+25%0.001-12761%0.002-8020%0.025-627%
Usd Book Value--37085000.00045193000.000-18%60218893.750-38%55585905.950-33%45223530.323-18%
Usd Book Value Change Per Share---0.134-0.167+25%0.001-12770%0.002-8021%0.025-627%
Usd Book Value Per Share--0.7870.986-20%1.335-41%1.229-36%1.000-21%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.285-0.276-3%-0.294+3%-0.253-11%-0.216-24%
Usd Free Cash Flow---10958000.000-9990750.000-9%-10494175.000-4%-2248873.050-79%-2999043.226-73%
Usd Free Cash Flow Per Share---0.232-0.218-6%-0.233+0%-0.049-79%-0.066-72%
Usd Free Cash Flow To Equity Per Share---0.131-0.154+17%0.065-302%0.166-179%0.181-172%
Usd Market Cap73550979.000-69%124461450.960139219088.365-11%140446271.250-11%410184819.398-70%322364079.547-61%
Usd Price Per Share1.630-62%2.6403.040-13%3.113-15%9.081-71%7.138-63%
Usd Profit---13434000.000-12708000.000-5%-13232738.750-1%-11470302.550-15%-9627047.548-28%
Usd Revenue--1821000.0001372500.000+33%311306.750+485%1414446.100+29%949404.065+92%
Usd Total Gains Per Share---0.134-0.167+25%0.001-12761%0.002-8020%0.025-627%
 EOD+3 -5MRQTTM+12 -22YOY+11 -255Y+7 -2910Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Cue Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.430
Price to Book Ratio (EOD)Between0-12.072
Net Profit Margin (MRQ)Greater than0-7.377
Operating Margin (MRQ)Greater than0-7.510
Quick Ratio (MRQ)Greater than12.940
Current Ratio (MRQ)Greater than13.012
Debt to Asset Ratio (MRQ)Less than10.397
Debt to Equity Ratio (MRQ)Less than10.659
Return on Equity (MRQ)Greater than0.15-0.362
Return on Assets (MRQ)Greater than0.05-0.218
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cue Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.996
Ma 20Greater thanMa 501.816
Ma 50Greater thanMa 1002.001
Ma 100Greater thanMa 2002.376
OpenGreater thanClose1.500
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets61,530
Total Liabilities24,445
Total Stockholder Equity37,085
 As reported
Total Liabilities 24,445
Total Stockholder Equity+ 37,085
Total Assets = 61,530

Assets

Total Assets61,530
Total Current Assets51,454
Long-term Assets10,076
Total Current Assets
Cash And Cash Equivalents 48,514
Net Receivables 1,698
Other Current Assets 1,242
Total Current Assets  (as reported)51,454
Total Current Assets  (calculated)51,454
+/-0
Long-term Assets
Property Plant Equipment 7,118
Long-term Assets Other 2,807
Long-term Assets  (as reported)10,076
Long-term Assets  (calculated)9,925
+/- 151

Liabilities & Shareholders' Equity

Total Current Liabilities17,081
Long-term Liabilities7,364
Total Stockholder Equity37,085
Total Current Liabilities
Short-term Debt 7,331
Short Long Term Debt 3,963
Accounts payable 3,501
Other Current Liabilities 4,137
Total Current Liabilities  (as reported)17,081
Total Current Liabilities  (calculated)18,932
+/- 1,851
Long-term Liabilities
Capital Lease Obligations 6,530
Long-term Liabilities  (as reported)7,364
Long-term Liabilities  (calculated)6,530
+/- 834
Total Stockholder Equity
Common Stock47
Retained Earnings -301,190
Other Stockholders Equity 338,228
Total Stockholder Equity (as reported)37,085
Total Stockholder Equity (calculated)37,085
+/-0
Other
Capital Stock47
Cash and Short Term Investments 48,514
Common Stock Shares Outstanding 47,144
Current Deferred Revenue2,112
Liabilities and Stockholders Equity 61,530
Net Debt -33,819
Net Invested Capital 45,250
Net Working Capital 34,373
Property Plant and Equipment Gross 10,734
Short Long Term Debt Total 14,695



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-12-31
> Total Assets 
7,315
0
16,279
10,242
10,242
6,295
66,954
59,326
53,114
44,582
45,363
45,188
41,756
45,209
71,605
60,649
101,353
106,617
99,534
88,721
89,672
78,875
83,401
90,704
84,749
76,300
91,283
81,682
73,163
68,888
61,530
61,53068,88873,16381,68291,28376,30084,74990,70483,40178,87589,67288,72199,534106,617101,35360,64971,60545,20941,75645,18845,36344,58253,11459,32666,9546,29510,24210,24216,27907,315
   > Total Current Assets 
6,507
0
15,138
8,169
8,169
4,131
65,065
55,929
49,250
40,611
40,610
31,968
29,868
32,990
61,025
51,190
88,353
93,563
87,527
77,405
79,677
70,255
68,468
75,947
69,004
61,700
77,187
68,755
60,935
57,517
51,454
51,45457,51760,93568,75577,18761,70069,00475,94768,46870,25579,67777,40587,52793,56388,35351,19061,02532,99029,86831,96840,61040,61149,25055,92965,0654,1318,1698,16915,13806,507
       Cash And Cash Equivalents 
6,406
0
14,926
7,307
7,307
3,400
63,534
53,102
45,736
15,842
20,800
21,913
24,261
31,379
44,290
23,432
59,749
71,729
74,866
73,257
73,920
67,633
64,371
67,927
66,126
29,726
51,614
56,321
52,901
54,691
48,514
48,51454,69152,90156,32151,61429,72666,12667,92764,37167,63373,92073,25774,86671,72959,74923,43244,29031,37924,26121,91320,80015,84245,73653,10263,5343,4007,3077,30714,92606,406
       Short-term Investments 
50
0
50
50
50
50
50
50
50
23,339
18,413
8,966
3,995
0
15,120
25,298
25,179
20,074
10,003
10,003
0
0
0
0
0
29,457
24,675
9,878
4,988
0
0
004,9889,87824,67529,4570000010,00310,00320,07425,17925,29815,12003,9958,96618,41323,33950505050505050050
       Net Receivables 
0
0
0
0
477
294
852
1,383
0
0
0
0
522
610
755
605
1,228
457
1,417
1,413
1,904
771
3,143
6,052
736
796
57
196
1,135
1,661
1,698
1,6981,6611,135196577967366,0523,1437711,9041,4131,4174571,22860575561052200001,3838522944770000
       Other Current Assets 
51
0
162
658
154
145
403
884
3,464
1,380
1,347
1,039
1,040
1,001
860
1,855
2,197
1,303
1,241
2,735
3,853
1,851
955
1,968
2,142
1,721
841
2,360
1,911
1,165
1,242
1,2421,1651,9112,3608411,7212,1421,9689551,8513,8532,7351,2411,3032,1971,8558601,0011,0401,0391,3471,3803,464884403145154658162051
   > Long-term Assets 
0
0
1,140
0
2,073
2,165
1,889
3,397
3,865
3,971
4,753
13,220
11,888
12,219
10,580
9,459
13,000
13,054
12,006
11,316
9,995
8,620
14,933
14,757
15,745
14,600
14,096
12,927
12,229
11,372
10,076
10,07611,37212,22912,92714,09614,60015,74514,75714,9338,6209,99511,31612,00613,05413,0009,45910,58012,21911,88813,2204,7533,9713,8653,3971,8892,1652,07301,14000
       Property Plant Equipment 
709
0
1,023
1,657
1,657
1,741
1,691
2,423
2,763
2,869
2,781
11,286
9,887
8,687
7,184
6,133
9,742
9,615
8,882
8,442
7,080
5,708
11,922
11,802
11,664
11,203
10,702
9,825
8,979
8,125
7,118
7,1188,1258,9799,82510,70211,20311,66411,80211,9225,7087,0808,4428,8829,6159,7426,1337,1848,6879,88711,2862,7812,8692,7632,4231,6911,7411,6571,6571,0230709
       Intangible Assets 
0
0
0
175
175
175
175
175
175
175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000175175175175175175175000
       Long-term Assets Other 
0
0
117
0
241
249
23
799
927
927
1,972
1,934
2,001
3,532
3,396
3,326
3,258
3,439
-6,878
2,874
2,915
2,912
3,011
2,955
3,931
3,247
3,244
3,102
3,100
3,097
2,807
2,8073,0973,1003,1023,2443,2473,9312,9553,0112,9122,9152,874-6,8783,4393,2583,3263,3963,5322,0011,9341,97292792779923249241011700
> Total Liabilities 
377
0
1,104
1,580
1,580
1,915
5,347
4,084
3,882
5,178
11,392
20,450
21,475
18,187
17,021
15,413
21,199
19,064
20,622
19,052
16,762
15,355
17,909
26,031
24,993
25,536
25,601
26,665
27,159
26,222
24,445
24,44526,22227,15926,66525,60125,53624,99326,03117,90915,35516,76219,05220,62219,06421,19915,41317,02118,18721,47520,45011,3925,1783,8824,0845,3471,9151,5801,5801,1040377
   > Total Current Liabilities 
342
0
1,068
1,580
1,580
1,915
5,347
4,084
2,963
4,585
6,217
10,573
11,268
10,392
11,655
12,090
14,862
14,227
16,316
16,633
16,673
15,355
12,788
11,411
8,323
10,222
11,549
13,810
16,307
17,207
17,081
17,08117,20716,30713,81011,54910,2228,32311,41112,78815,35516,67316,63316,31614,22714,86212,09011,65510,39211,26810,5736,2174,5852,9634,0845,3471,9151,5801,5801,0680342
       Short-term Debt 
0
0
0
0
0
0
2,500
2,309
-19
1,398
0
3,644
4,036
4,434
4,448
4,515
4,249
4,569
4,777
4,989
4,874
3,633
4,932
5,388
3,196
4,298
5,263
6,295
7,328
7,362
7,331
7,3317,3627,3286,2955,2634,2983,1965,3884,9323,6334,8744,9894,7774,5694,2494,5154,4484,4344,0363,64401,398-192,3092,500000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
3,644
0
0
0
0
0
0
0
0
0
0
0
0
0
963
1,963
2,963
3,963
3,963
3,963
3,9633,9633,9632,9631,96396300000000000003,64400000000000
       Accounts payable 
178
0
550
772
772
772
1,329
1,166
546
997
2,035
2,893
2,289
1,178
883
1,740
1,289
1,108
2,070
2,523
2,992
2,470
2,591
2,617
1,568
2,045
2,731
2,151
2,356
2,480
3,501
3,5012,4802,3562,1512,7312,0451,5682,6172,5912,4702,9922,5232,0701,1081,2891,7408831,1782,2892,8932,0359975461,1661,3297727727725500178
       Other Current Liabilities 
164
0
1,068
250
1,526
1,758
894
268
1,218
1,095
2,170
2,149
2,580
1,555
2,227
1,144
4,061
2,584
2,787
1,976
2,003
3,989
4,620
3,406
3,559
3,879
3,554
2,843
4,076
5,127
4,137
4,1375,1274,0762,8433,5543,8793,5593,4064,6203,9892,0031,9762,7872,5844,0611,1442,2271,5552,5802,1492,1701,0951,2182688941,7581,5262501,0680164
   > Long-term Liabilities 
0
0
36
0
0
0
0
2,918
919
593
5,175
9,877
10,207
7,795
5,366
3,323
6,337
4,837
4,306
2,419
89
0
5,121
14,620
16,670
15,314
14,052
12,855
10,852
9,015
7,364
7,3649,01510,85212,85514,05215,31416,67014,6205,1210892,4194,3064,8376,3373,3235,3667,79510,2079,8775,1755939192,91800003600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,861
9,913
0
8,035
7,077
6,118
0
0
006,1187,0778,03509,9139,86100000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-2,500
-2,309
19
-1,398
0
4,947
3,787
2,610
1,348
194
4,182
3,633
2,369
1,085
0
0
5,121
4,759
6,757
5,358
4,055
2,370
635
-108
-801
-801-1086352,3704,0555,3586,7574,7595,121001,0852,3693,6334,1821941,3482,6103,7874,9470-1,39819-2,309-2,500000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
2,909
919
593
5,175
4,947
10,207
7,795
5,366
3,323
6,337
4,837
4,306
2,419
89
0
5,121
4,759
6,757
0
6,018
5,778
4,734
0
0
004,7345,7786,01806,7574,7595,1210892,4194,3064,8376,3373,3235,3667,79510,2074,9475,1755939192,9090000000
       Deferred Long Term Liability 
34
0
36
0
0
0
0
9
0
0
384
347
326
377
0
194
128
61
260
0
0
0
0
0
0
0
0
0
0
0
0
000000000000260611281940377326347384009000036034
> Total Stockholder Equity
6,938
0
15,175
15,175
8,662
4,381
61,607
55,242
49,232
39,404
33,971
24,738
20,281
27,022
54,584
45,236
80,154
87,553
78,911
69,669
72,910
63,520
65,492
64,673
59,756
50,764
65,683
55,017
46,004
42,666
37,085
37,08542,66646,00455,01765,68350,76459,75664,67365,49263,52072,91069,66978,91187,55380,15445,23654,58427,02220,28124,73833,97139,40449,23255,24261,6074,3818,66215,17515,17506,938
   Common Stock
7
0
11
11
11
11
20
20
20
20
21
21
21
23
27
27
29
30
30
31
31
32
32
34
35
35
43
43
44
45
47
474544434335353432323131303029272723212121202020201111111107
   Retained Earnings Total Equity00-276,750-263,565-250,457-235,864-224,909-211,701-197,446-189,062-176,069-165,790-153,285-142,182-132,151-121,318-108,500-99,583-92,592-83,068-71,801-60,180-47,629-40,3440000000
   Accumulated Other Comprehensive Income 
0
0
-247
0
-416
-540
-661
-828
-968
-20
-11
-3
-1,638
-1,832
-10
249
155
72
7
7
0
0
0
0
0
-92
-96
-39
-5
0
0
00-5-39-96-92000007772155249-10-1,832-1,638-3-11-20-968-828-661-540-4160-24700
   Capital Surplus 
0
0
0
0
0
0
0
95,566
96,841
99,584
105,763
107,788
112,852
126,582
163,068
166,278
212,121
229,633
232,159
235,428
248,948
252,550
262,906
276,340
284,630
286,685
316,192
318,578
322,715
0
0
00322,715318,578316,192286,685284,630276,340262,906252,550248,948235,428232,159229,633212,121166,278163,068126,582112,852107,788105,76399,58496,84195,5660000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
0
24,998
0
26,417
27,292
95,069
96,394
97,809
99,584
105,763
107,788
112,852
126,582
163,068
166,278
212,121
229,633
232,159
235,428
248,948
252,550
262,906
276,340
284,630
286,685
316,192
318,578
322,715
330,376
338,228
338,228330,376322,715318,578316,192286,685284,630276,340262,906252,550248,948235,428232,159229,633212,121166,278163,068126,582112,852107,788105,76399,58497,80996,39495,06927,29226,417024,99800



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,490
Cost of Revenue-3,436
Gross Profit2,0542,054
 
Operating Income (+$)
Gross Profit2,054
Operating Expense-54,046
Operating Income-51,992-51,992
 
Operating Expense (+$)
Research Development40,276
Selling General Administrative16,680
Selling And Marketing Expenses2,910
Operating Expense54,04659,866
 
Net Interest Income (+$)
Interest Income2,661
Interest Expense-1,245
Other Finance Cost-0
Net Interest Income1,416
 
Pretax Income (+$)
Operating Income-51,992
Net Interest Income1,416
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-50,733-53,251
EBIT - interestExpense = -53,237
-50,733
-49,488
Interest Expense1,245
Earnings Before Interest and Taxes (EBIT)-51,992-49,488
Earnings Before Interest and Taxes (EBITDA)-48,556
 
After tax Income (+$)
Income Before Tax-50,733
Tax Provision-0
Net Income From Continuing Ops-50,733-50,733
Net Income-50,733
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses57,482
Total Other Income/Expenses Net1,259-1,416
 

Technical Analysis of Cue Biopharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cue Biopharma. The general trend of Cue Biopharma is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cue Biopharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cue Biopharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.7 < 1.77 < 2.08.

The bearish price targets are: .

Tweet this
Cue Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cue Biopharma. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cue Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cue Biopharma. The current macd is -0.10970523.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cue Biopharma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cue Biopharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cue Biopharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cue Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartCue Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cue Biopharma. The current adx is 14.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cue Biopharma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cue Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cue Biopharma. The current sar is 1.94246208.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cue Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cue Biopharma. The current rsi is 40.00. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Cue Biopharma Daily Relative Strength Index (RSI) ChartCue Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cue Biopharma. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cue Biopharma price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cue Biopharma Daily Stochastic Oscillator ChartCue Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cue Biopharma. The current cci is -169.02731337.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cue Biopharma Daily Commodity Channel Index (CCI) ChartCue Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cue Biopharma. The current cmo is -21.14508772.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cue Biopharma Daily Chande Momentum Oscillator (CMO) ChartCue Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cue Biopharma. The current willr is -73.7704918.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cue Biopharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cue Biopharma Daily Williams %R ChartCue Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cue Biopharma.

Cue Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cue Biopharma. The current atr is 0.16311917.

Cue Biopharma Daily Average True Range (ATR) ChartCue Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cue Biopharma. The current obv is -13,592,960.

Cue Biopharma Daily On-Balance Volume (OBV) ChartCue Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cue Biopharma. The current mfi is 34.65.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cue Biopharma Daily Money Flow Index (MFI) ChartCue Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cue Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Cue Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cue Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.996
Ma 20Greater thanMa 501.816
Ma 50Greater thanMa 1002.001
Ma 100Greater thanMa 2002.376
OpenGreater thanClose1.500
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cue Biopharma with someone you think should read this too:
  • Are you bullish or bearish on Cue Biopharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cue Biopharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cue Biopharma

I send you an email if I find something interesting about Cue Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Cue Biopharma.

Receive notifications about Cue Biopharma in your mailbox!